President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs. ^[1] Kyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more. ^[2] The stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program. ^[3] Health Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals. ^[4] The nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles. ^[5] UCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals. ^[6] A majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks. ^[7] The pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business. ^[8]